Article (Scientific journals)
Sputum Type 2 Markers Could Predict Remission in Severe Asthma Treated With Anti-IL-5.
Moermans, Catherine; Brion, C; BOCK, Grégory et al.
2023In CHEST
Peer Reviewed verified by ORBi
 

Files


Full Text
Sputum Type 2 Markers Could Predict Remission in Severe Asthma Treated With Anti-IL-5 Elsevier Enhanced Reader.pdf
Author postprint (7.47 MB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
asthma; biotherapy; remission; sputum; Cardiology and Cardiovascular Medicine; Critical Care and Intensive Care Medicine; Pulmonary and Respiratory Medicine
Abstract :
[en] [en] BACKGROUND: Biotherapies targeting IL-5 allow a tangible improvement of asthma. However, all patients do not respond the same way to these treatments. Even if high blood eosinophil counts seem to be associated with a reduction in exacerbations with treatment targeting IL-5, we lack biomarkers for the prediction of remission after these very expensive treatments. RESEARCH QUESTION: Does the sputum of patients with severe eosinophilic asthma show biomarkers of remission after therapy targeting IL-5? STUDY DESIGN AND METHODS: This observational study included 52 patients with severe asthma initiated with anti-IL-5 therapy and recruited from the asthma clinic of the CHU of Liege, Belgium. Remission was defined as patients who combined the following at 1 year after therapy: no chronic treatment with oral corticosteroids; no exacerbation; asthma control questionnaire score < 1.5, asthma control test score > 19, or both; FEV1 of ≥ 80% predicted, improvement of FEV1 of ≥ 10%, or both; and a blood eosinophil count < 300 cells/μL. Eosinophil peroxidase (EPX), IgE, IL-3, IL-4, IL-5, IL-13, IL-25, IL-33, granulocyte-macrophage colony-stimulating factor, thymic stromal lymphopoietin (TSLP), and eotaxin-1 levels were measured in the sputum of these patients before anti-IL-5 treatment. RESULTS: Among the 52 patients, 11 were classified as being in remission. These patients were characterized by higher sputum eosinophil, macrophage, and lymphocyte counts, whereas the sputum neutrophil percentage was lower than in the nonremission group. In addition, the sputum eotaxin-1, TSLP, IL-5, EPX, and IgE protein levels were higher at baseline in the remission group compared with the nonremission group. Univariate regression analysis revealed that male vs female sex, sputum neutrophil percentage, eotaxin-1, IL-5, and EPX were potential predictors of remission. INTERPRETATION: Sputum type 2 markers seemed to be potentially predictive of remission after anti-IL-5 therapy in a cohort of patients with severe eosinophilic asthma. These results need validation on a larger cohort.
Disciplines :
Life sciences: Multidisciplinary, general & others
Author, co-author :
Moermans, Catherine  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
Brion, C;  Haute École de la Province de Liège, Liege, Belgium
BOCK, Grégory ;  Centre Hospitalier Universitaire de Liège - CHU > > Service d'anatomie et cytologie pathologiques ; Haute École Charlemagne, Liege, Belgium
Graff, Sophie ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
Gerday, Sara  ;  Université de Liège - ULiège > Département des sciences cliniques > Pneumologie - Allergologie
Nekoee, H;  Department of Public Health, CHU and University of Liege, Liege, Belgium
Poulet, Christophe  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de rhumatologie
Bricmont, Noémie ;  Université de Liège - ULiège > Département des sciences cliniques > Pédiatrie cardiologique et pneumologique
Henket, Monique ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
PAULUS, Virginie ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
GUISSARD, Françoise ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
Louis, Renaud ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
Schleich, FLorence ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
More authors (3 more) Less
Language :
English
Title :
Sputum Type 2 Markers Could Predict Remission in Severe Asthma Treated With Anti-IL-5.
Publication date :
03 February 2023
Journal title :
CHEST
ISSN :
0012-3692
eISSN :
1931-3543
Publisher :
Elsevier BV, United States
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 09 June 2023

Statistics


Number of views
53 (10 by ULiège)
Number of downloads
29 (2 by ULiège)

Scopus citations®
 
12
Scopus citations®
without self-citations
8
OpenCitations
 
0

Bibliography


Similar publications



Contact ORBi